Scholar Rock Shares Climb After FDA BLA Resubmission for SMA Therapy
Scholar Rock (NASDAQ: SRRK) saw its stock jump 12% after the company resubmitted a Biologics License Application for apitegromab, a therapy for spinal muscular atrophy. The resubmission names Catalent Indiana LLC, part of Novo Nordisk, and an additional U.S.-based fill-finish facility. The company expects FDA acceptance within 30 days and a review …